-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Pulmonary hypertension (PH) is a multi-causal disease with a rising global incidence, eventually leading to right ventricular failure
Recently, an authoritative journal in the field of internal medicine published a research article in the Journal of Internal Medicine.
Non-alcoholic fatty liver
Between 2005 and 2019, a total of 9455 PH patients were followed up in general and internal medicine, and tended to be based on age, gender, annual consultation frequency, and related comorbid diseases (obesity, diabetes , heart failure, abnormal lipid metabolism) Score
diabetes
Cumulative incidence of NAFLD in PH and non-PH patients
Within 10 years, the cumulative incidence of NAFLD in PH patients (7.
The data from this study indicate that the incidence of NAFLD is significantly increased in PH patients
The incidence of NAFLD is significantly increased in PH patients
Original source:
Markus S.
Pulmonary hypertension is associated with an increased incidence of NAFLD: A retrospective cohort study of 18,910 patients
in this message